MPAs may reflect genetic risk for schizophrenia

NewsGuard 100/100 Score

By Mark Cowen, Senior medwireNews Reporter

Minor physical anomalies (MPAs) are more common in schizophrenia patients and their unaffected siblings than in mentally healthy individuals without a family history of the disorder, research shows.

Indeed, Leila Gassab and colleagues from the University of Monastir in Tunisia found that schizophrenia patients had a significantly higher rate of MPAs than their siblings, who, in turn, had a significantly higher rate of MPAs than mentally healthy controls.

"MPAs appear to reflect the degree of psychosis proneness," comment the researchers in Comprehensive Psychiatry.

The team assessed 93 patients with schizophrenia, 59 of their mentally healthy siblings, and 71 age- and gender-matched mentally healthy controls for the presence of MPAs in six body areas (head, eyes, ears, mouth, hands, and feet) using a standardized scale derived from the Waldrop Scale.

Patients with schizophrenia were also assessed using the Positive and Negative Syndrome Scale (PANSS), the Global Assessment of Functioning (GAF), and the Clinical Global Impression-Severity (CGI-S).

The researchers found that the prevalence of MPAs was significantly higher in schizophrenia patients than in siblings and controls, at 60.2% versus 33.9% and 12.7%, respectively. The difference between siblings and controls was also significant.

Schizophrenia patients also had significantly higher total MPA scores on the Waldrop-derived scale than siblings and controls, at 4.6 versus 3.0 and 1.9, respectively. Again, the difference in MPA score between siblings and controls was significant.

In patients with schizophrenia, MPA scores were significantly and negatively correlated with age at disease onset and age at first hospitalization, and positively correlated with number of hospitalizations.

There was also a significant positive correlation between MPA scores and PANSS total and negative subscale scores, and CGI severity score. However, no significant correlation was found between MPA score and GAF score.

"The increased rates of MPAs, found in the non-ill siblings of patients with schizophrenia serve as a reminder that the families of patients manifest a range of 'vulnerability' characteristics, which are not 'sufficient' for the later development of schizophrenia," comment Gassab et al.

They conclude: "MPAs should be considered as markers of a generalized early neuromaldevelopment, and as markers of a specific [severe] clinical subtype of schizophrenia."

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Comments

  1. gerald bouthner gerald bouthner United States says:

    I am always glad to see researchers busy trying to identify early markers for various illnesses. I am hopeful as are many doctors and researchers that by identifying early markers in mental illnesses like schizophrenia it will lead to earlier treatment plans for the patient and limit it's severity level in the patient.

  2. Stefan Andersson Stefan Andersson Sweden says:

    Can not any difference which gives you the sense of not belonging in a social context cause an elevated risk of developing an integration disorder like this?

    How do you explain the fact that belonging to an ethnic minority increases the risk of developing an integration disorder like this?

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals human gut plasmid with biomarker potential